Oclatinib: alternativa terapéutica para el hemangioma cutáneo canino
DOI:
https://doi.org/10.34117/bjdv10n7-042Keywords:
oclacitinib, canino, hemangioma, neoplasiaAbstract
Los hemangiomas cutáneos son tumores que se originan en las células endoteliales de la pared de los vasos sanguíneos, muy frecuente en caninos. Son predisponentes los animales con pelo corto y claro. Debido a la naturaleza de la neoplasia, la hemorragia local es el problema más frecuente e intolerable para los tutores y pacientes, por eso la resolución quirúrgica es el tratamiento de elección, con alta tasa de reincidencia. La patogenia del HC no se conoce bien; sin embargo, tanto la vasculogénesis como la angiogénesis se asocian con la génesis del hemangioma. La presente revisión proporciona una visión general integrada sobre la naturaleza del hemangioma, factores de señalización de la génesis neoplásica vascular y los factores de crecimiento endotelial vascular asociados con la neovascularización y la génesis del hemangioma. Lo cual, permite comprender la respuesta terapéutica de un canino con múltiples hemangiomas cutáneos tratado con oclacitinib; fármaco que inhibe preferentemente JAK1/ JAK2, y otras quinasas no JAK entre los cuales se menciona 41% de inhibición del receptor 2 del factor de crecimiento endotelial vascular (VEGFR-2/FLK1), el cual es una de las vías desregularizadas en el hemangioma. Enfatizando el conocimiento de las vías de señalización tumoral, se planean alternativas terapéuticas conservadoras con el Oclacitinib como potencial "interruptor angiogénico". Éste es el primer estudio que señala el beneficio clínico y la eficacia de oclacitinib en perros con neoformación vascular cutánea.
References
AITA N. Hemangioma of the ileum in a dog. J Vet Med Sci 2010;72:1071-1073.
AITTOMÄKI S., Pesu M. Therapeutic targeting of the Jak/STAT pathway. Basic Clin. Pharmacol. Toxicol. 2014;114:18–23.
AMBLER C.A., Schmunk G.M., Bautch V.L. Stem cell-derived endothelial cells/progenitors migrate and pattern in the embryo using the VEGF signaling pathway. Dev. Biol. 2003;257:205–219.
ANGELINI J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, Brancati S, Scaglione F. JAK-Inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. Biomolecules. 2020;10:1002
Apoquel Product Label (United States). Zoetis Inc., Florham Park, NJ, USA. Available at: http://www.apoquel.com. Accessed Jun 10, 2024.
Apoquel Statement of Product Characteristics (European Union). Zoetis Belgium SA, Louvain-la-Neuve, Belgium. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/002688/WC500152091.pdf. Accessed Jun 10, 2024.
Arquero, N. Citología diagnostica veterinaria Editorial. El manual Moderno. D.F-Santafé de Bogotá –México 2002. pp.1-5, 39-43, 129-132
ASLAN J, Shipstone MA, Sullivan LM. Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report. Vet Dermatol. 2021;32(4):398-e113.
BARRETT LE, Gardner HL, Barber LG, Sadowski A, London CA. Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study. BMC Vet Res. 2019;15(1):291
BANERJEE S, Biehl A, Gadina M, Hasni S, Schwartz D.M. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs. 2017;77:521–546.
BERARD M., Sordello S., Ortega N., Carrier J.L., Peyri N., Wassef M., Bertrand N., Enjolras O., Drouet L., Plouet J. Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas. Am. J. Pathol. 1997;150:1315–1326.
BOTTOS A., Bardelli A. Oncogenes and angiogenesis: A way to personalize anti-angiogenic therapy? Cell. Mol. Life Sci. 2013;70:4131–4140
BOYE E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107: 745-752.
BOYE E., Olsen B.R. Signaling mechanisms in infantile hemangioma. Curr. Opin. Hematol. 2009;16:202–208.
BRYAN M, Rajapaksa N. Kinase inhibitors for the treatment of immunological disorders: Recent advances. J. Med. Chem. 2018;61:9030–9058.
BUCHERT M, Burns C, Ernst M. Targeting JAK kinase in solid tumors: Emerging opportunities and challenges. Oncogene. 2016;35:939–951
CASIMIRO-GARCIA A, Trujillo J, Vajdos F, Juba B, Banker M, Aulabaugh A et al. Identification of cyanamide-based Janus kinase 3 (JAK3) covalent inhibitors. J. Med. Chem. 2018;61:10665–10699.
DE QUEIROZ S, De Lima V, Amorim PHGH, Statkievicz C, Magro-Filho O. Severe Edema After Sclerotherapy of Labial Hemangioma With Ethamolin Oleate in a Young Child. Journal of Craniofacial Surgery. 2016 Sep;27(6):e567–8.
DOBSON J, Samuel S, Milstein H, Rogers G, Wood J. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. 2002;240-246
Ferrara N., Adamis A.P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 2016;15:385–403
FORSTER M, Chaikuad A, Bauer S, Holstein J, Robers M, Corona C, Gehringer M et al. Selective JAK3 Inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chem. Biol. 2016;23:1335–1340
GEIGER J, Grandis J, Bauman J. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016;56:84–92.
Greenberger S., Bischoff J. Pathogenesis of infantile haemangioma. Br. J. Dermatol. 2013;169:12–19.
GONZALES A, Bowman J, Fici G, Zhang M, Mann D, Mitton-Fry M. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J. Vet. Pharmacol. Ther. 2014;37:317–324.
HAMMARÉN H, Virtanen A, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118:48–63.
Harris C, Cummings J. JAK1 inhibition and inflammatory bowel disease. Rheumatology. 2021;60: 45- 51.
HIDANO, A, Nakajima S. Earliest features of the strawberry mark in the newborn. Br J Dermatol 1972; 87: 138-144.
HOFFMAN K. An Unusual Complication of Facial Sclerotherapy. Dermatologic Surgery. 2003 Apr;29(4):423–4
ITINTEANG T, Tan S, Brasch H, Steel R, Best H, Vishvanath A, Jia J, Day D. Infantile haemangioma expresses embryonic stem cell markers. J. Clin. Pathol. 2012;65:394–398
JAYSON C, Kerbel R, Ellis L, Harris A. Antiangiogenic therapy in oncology: Current status and future directions. Lancet. 2016; 388:518–529
JINNIN M., Medici D., Park L., Limaye N., Liu Y., Boscolo E., Bischoff J., Vikkula M., Boye E., Olsen B.R. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat. Med. 2008;14:1236–1246.
KIU H, Nicholson S. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012;30:88–106.
KIUPEL, M. Surgical pathology of tumors of domestic animals. 3rd ed, Vol. 3: Tumors of soft tissue, Davis-Thompson Foundation, Gurnee (2020)
LEROY E, Constantinescu S. Rethinking JAK2 inhibition: Towards novel strategies of more specific and versatile Janus kinase inhibition. Leukemia. 2017;31:1023–1038
LI P, Guo Z, Gao Y, Pan W. Propranolol represses infantile hemangioma cell growth through the B2-adrenergic receptor in a HIF-1α dependent manner. Oncol. Rep. 2015;33:3099–3107.
LU Z, Hong C, Jark P, et al. JAK1/2 inhibitors AZD1480 and CYT387 inhibit canine B-cell lymphoma growth by increasing apoptosis and disrupting cell proliferation. J Vet Intern Med. 2017;31(6):1804–1815
MABETA P., Pepper M.S. Hemangiomas-current therapeutic strategies. Int. J. Dev. Biol. 2011;55:431–437.
MABETA P., Pepper M.S. Inhibition of hemangioma development in a syngeneic mouse model correlates with Bcl-2 suppression and the inhibition of Akt kinase activity. Angiogenesis. 2012;15:131–139.
MABETA P. Inhibition of phosphoinositide 3-kinase is associated with reduced angiogenesis and an altered expression of angiogenic markers in endothelioma cells. Biomed. Pharmacother. 2014;68:611–617.
MABETA P. PF573, 228 inhibits vascular tumor cell growth, migration as well as angiogenesis, induces apoptosis and abrogates PRAS40 and S6RP phosphorylation. Acta Pharm. 2016;66:399–410.
MABETA P. Oncosuppressors and Oncogenes: Role in Haemangioma Genesis and Potential for Therapeutic Targeting. Int J Mol Sci. 2018 Apr 13;19(4):1192.
MENET C. A dual inhibition, a better solution: Development of a JAK1/TYK2 inhibitor. J. Med. Chem. 2018;61:8594–8596
Meuten, D. Tumors in domestic animals (5th ed.), Wiley Blackwell, Ames (2017), pp. 142-175
NORTH PE, Waner M, Mizeracki A, Mihm MC. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11-22
OLSSON A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling? In control of vascular function. Nat. Rev. Mol. Cell Biol. 2006;7:359–371.
PAN W., Li P., Guo Z., Huang Q., Gao Y. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Pediatr. Blood Cancer. 2015;62:1414–1420.
RAK J., Yu J., Klement G., Kerbel R. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc. 2000;5:24–33
ROCHA L, Peixoto A, Henriques J, Zancopé, K. Diferentes tipos e protocolos de esclerosantes vasculares no tratamento das más formações vasculares orais: revisão literária. Brazilian Journal of Health Review, [S. l.], v. 7, n. 2, p. e69117, 2024.
RODRIGUEZ S., Huynh-Do U. The role of PTEN in tumor angiogenesis. J. Oncol. 2012:1–11.
ROSA W, De Oliveira C, Carvalho D, Nespolo R, Gottardo V, Queiroz, P. Escleroterapia como conduta conservadora no tratamento de malformação vascular oral: relato de caso clínico.Brazilian Journal of Health Review,[S. l.], v. 6, n. 5, p. 25885–25897, 2023.
SCHWARTZ D, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 2017;16:843–862.
SHAWKY A, Almalki F, Abdalla A, Abdelazeem A, Gouda A. A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics. 2022 May 6;14(5):1001.
SHEN Y, Liu Y, Ke X, Kang H, Hu G, Hong S. Association between JAK1 gene polymorphisms and susceptibility to allergic rhinitis. Asian Pac. J. Allergy Immunol. 2016;34:124–129.
THOMAS J, Snowden J, Zeidler M, Danson S. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015;113(3):365–371.
YE W. The complexity of translating anti-angiogenesis therapy from basic science to the clinic. Dev. Cell. 2016;37:114–125
JI Y., Chen S., Li K., Li L., Xu C., Xiang B. Signaling pathways in the development of infantile hemangioma. J. Hematol. Oncol. 2014;7:3–13.
VAINCHENKER W, Leroy E, Gilles L, Marty C, Plo I. Constantinescu S.N. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research. 2018;7:82.
VERMA K, Tran D, Bryan B, Mitchell D. Meta-analysis of infantile hemangioma endothelial cell microarray expression data reveals significant aberrations of gene networks involved in cell adhesion and extracellular matrix composition. Angiol. Open Access. 2013;1:107.
VIRTANEN A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33:15–32
WANG Y., Chen J., Tang W., Zhang Y., Li X. Rapamycin inhibits the proliferation of endothelial cells in hemangioma by blocking the mTOR-FABP4 pathway. Biomed. Pharmacother. 2017;85:272–279.
WILLS-KARP M, Luyimbazi J, Xu X, Schofield B, Neben T, Karp C, Donaldson D. Interleukin-13: Central mediator of allergic asthma. Science. 1998;282:2258–2261
WONG A, Hirpara J, Pervaiz S, Eu J, Sethi G, Goh B. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin. Investig. Drugs. 2017;26:883–887
WROBLESKI S, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: Discovery of the allosteric inhibitor BMS-986165. J. Med. Chem. 2019;62:8973–8995.
XU P, Shen P, Yu B, Xu X, Ge R, Cheng X, Chen Q, Bian J, Li Z, Wang J. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur. J. Med. Chem. 2020;192:112155
YAMAOKA K, Saharinen P, Pesu M, Holt V., 3rd, Silvennoinen O., O’Shea J.J. The Janus kinases (Jaks) Genome Biol. 2004;5:253.
YASUDA T, Fukada T, Nishida K, Nakayama M, Matsuda M, Miura I, Dainichi T, Fukuda S, Kabashima K, Nakaoka S, et al. Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. J. Clin. Investig. 2016;126:2064–2076.
YU Y., Flint A.F., Mulliken J.B., Wu J.K., Bischoff J. Endothelial progenitor cells in infantile hemangioma. Blood. 2004;103:1373–1375
ZAK M, Hanan E, Lupardus P, Brown D, Robinson C, Siu M, Lyssikatos J, Romero F, Zhao G, Kellar T, et al. Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. Bioorg. Med. Chem. Lett. 2019;29:1522–1531.
ZHOU J, Ong C, Hur G, Shen H. Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem. Pharmacol. 2010;79:1242–1250.
